A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes a higher complication rate with Covid-19 versus the flu.
A rheumatoid arthritis drug developed by Genentech proved to be effective in benefitting patients who have Covid-19-associated pneumonia, according to new late-stage clinical trial data.
Sanofi announced disappointing results from a Phase III study of intravenously dosed Kevzara (sarilumab) in which hospitalized Covid-19 patients failed to meet primary and secondary endpoints.
Regeneron Pharmaceuticals – with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) – is launching Phase III trials of REGN-COV2, the company’s two-antibody cocktail for the treatment and prevention of COVID-19.
Regeneron Pharmaceuticals and Sanofi said their rheumatoid arthritis drug Kevzara failed to meet the main goals of a U.S. study testing the medicine in the most critically ill COVID-19 patients.
Lassen Therapeutics, based in San Diego, came out of stealth mode with a $31 million Series A financing round.
Eli Lilly will assess the company’s JAK1/JAK2 inhibitor Olumiant (baricitinib) as a potential treatment for COVID-19 in a Phase III study.
Novo Nordisk is expanding the company’s presence in treating kidney disease with the acquisition of U.S.-based Corvidia Therapeutics for $2.1 billion.
Roche and Gilead Sciences launched a Phase III clinical trial in severe COVID-19 pneumonia, testing Roche’s Actemra/RoActemra with Gilead’s remdesivir.
Regeneron and Sanofi dosed the first patient outside of the United States with the rheumatoid arthritis drug Kevzara as part of a second global clinical trial assessing the medication as a treatment for COVID-19, the disease caused by the novel coronavirus pandemic.